Quote:
Look at what has happened the past two years:

-Losing funding for a phase 2 (K at UoB - good preclinical stuff out about two years after we expected to start a funded phase 2 in AML)
-Having to do a phase 2b in order to get a maximum value partnership (Prurisol)
-Suffering massive delays in the B-OM trial completion completion.
-Indefinitely holding off on the crown jewel B-ABSSSI phase 3.
-Depending on the stock price for funding in the face of two large sellers (Aruda/Aspire) and high profile SA hit jobs along with a frivolous lawsuit.

So, I'm not going to dig up the numbers but since early 2015 more than 10 million shares have been sold into the market through Aspire and Aruda combined (that's a safe underestimate - and a documented fact). Aspire shares are new shares printed up by the company. Aruda's shares that he sold were ones that otherwise would have been safely tucked away in Dr. Menon's portfolio (unless you believe he would have sold as many as Aruda had).

As for the present (which I assume your unqualified statement was referring to) I don't believe Aruda is selling any more because he made a filing this year that was not required which I took as a wink that he's holding from that point on. Only the company knows if they are raising any more funding from Aspire. At this point it doesn't really matter with results coming and my post was discussing the last two years.

PS: Don't associate me with those imbeciles at iHub. You keep saying it so I'll keep refuting it - I obviously have a different view of this company than they do. I find Scotty's posts entertaining sometimes but those other guys are dopes with no vision. I hope they're short and get pinched hard.

PSS: A little haddock with a lemon glaze sounds good tonight. Thanks for the tip!